3.97
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Quiver Quantitative
Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest
Iovance Biotherapeutics’ Remarkable Surge: Time to Dive In? - StocksToTrade
Iovance Biotherapeutics’ Unexpected Surge: Is It Time to Buy? - timothysykes.com
Where are the Opportunities in (IOVA) - news.stocktradersdaily.com
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com
Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Evaxion Biotech, Inxmed, Aivita Biomedical, Iovance Biotherapeutics, Viralyt - MenaFN
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st
Iovance Biotherapeutics Inc Inc. (IOVA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Is Iovance Biotherapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside - Yahoo Finance
Iovance Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - printweek.in
Zacks Research Issues Pessimistic Estimate for IOVA Earnings - Defense World
What drives Iovance Biotherapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com
What analysts say about Iovance Biotherapeutics Inc. stockFree Stock Selection - jammulinksnews.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha
Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World
Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid potential - Investing.com
Iovance BioTherapeutics Sees Positive Trends with New Appointments and Promising Cancer Study - StocksToTrade
Iovance Biotherapeutics Appoints New Chief Financial Officer - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Iovance Biotherapeutics: Legal Woes Shake Investor Confidence - timothysykes.com
Iovance Biotherapeutics Faces Legal Hurdles Amid Investor Concerns - StocksToTrade
Iovance Biotherapeutics, Inc. Appoints Corleen Roche as Chief Financial Officer, Effective August 6, 2025 - MarketScreener
Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionMulti Bagger Alerts - Newser
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewswire
Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener
Iovance Biotherapeutics Names Corleen Roche as Chief Financial Officer - MarketScreener
Citizens JMP reiterates Market Perform rating on Iovance stock By Investing.com - Investing.com Canada
Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges - Investing.com Canada
Cambridge Investment Research Advisors Inc. Acquires 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Amtagvi shows 61% response rate in less heavily treated melanoma patients - Investing.com Australia
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025 - openPR.com
Levi & Korsinsky Reminds Iovance Investors of the Pending - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - The Globe and Mail
IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance - GlobeNewswire
FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
The Iovance Biotherapeutics Lawsuit: A Cautionary Tale of Investor Protection and Timely Legal Action - AInvest
Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - MarketScreener
Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study - MarketScreener
Iovance Biotherapeutics Reports 61% Response Rate for Amtagvi® in Third-Line Melanoma Patients - Nasdaq
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma - Yahoo Finance
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):